Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Nonsteroidal anti-inflammatory drugs may reduce enterohepatic recirculation of mycophenolic acid in patients with childhood-onset systemic lupus erythematosus.

Fukuda T, Brunner HI, Sagcal-Gironella AC, Vinks AA.

Ther Drug Monit. 2011 Oct;33(5):658-62. doi: 10.1097/FTD.0b013e318228195f.

2.

Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients.

Naesens M, Kuypers DR, Streit F, Armstrong VW, Oellerich M, Verbeke K, Vanrenterghem Y.

Clin Pharmacol Ther. 2006 Nov;80(5):509-21.

PMID:
17112807
3.

Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus.

Sherwin CM, Sagcal-Gironella AC, Fukuda T, Brunner HI, Vinks AA.

Br J Clin Pharmacol. 2012 May;73(5):727-40. doi: 10.1111/j.1365-2125.2011.04140.x.

4.

Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus.

Sagcal-Gironella AC, Fukuda T, Wiers K, Cox S, Nelson S, Dina B, Sherwin CM, Klein-Gitelman MS, Vinks AA, Brunner HI.

Semin Arthritis Rheum. 2011 Feb;40(4):307-13. doi: 10.1016/j.semarthrit.2010.05.007. Epub 2010 Jul 23.

5.

UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients.

Fukuda T, Goebel J, Cox S, Maseck D, Zhang K, Sherbotie JR, Ellis EN, James LP, Ward RM, Vinks AA.

Ther Drug Monit. 2012 Dec;34(6):671-9. doi: 10.1097/FTD.0b013e3182708f84.

6.

Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.

Staatz CE, Tett SE.

Clin Pharmacokinet. 2007;46(1):13-58. Review.

PMID:
17201457
7.

Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients.

Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y.

Transplantation. 2006 Oct 27;82(8):1074-84.

PMID:
17060857
8.

Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study.

Djabarouti S, Breilh D, Duffau P, Lazaro E, Greib C, Caubet O, Saux MC, Pellegrin JL, Viallard JF.

Arthritis Res Ther. 2010;12(6):R217. doi: 10.1186/ar3202. Epub 2010 Dec 22. Erratum in: Arthritis Res Ther. 2011;13(2):401.

9.

Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies.

Zahr N, Amoura Z, Debord J, Hulot JS, Saint-Marcoux F, Marquet P, Piette JC, Lechat P.

Clin Pharmacokinet. 2008;47(4):277-84.

PMID:
18336056
10.

Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.

Musuamba FT, Rousseau A, Bosmans JL, Senessael JJ, Cumps J, Marquet P, Wallemacq P, Verbeeck RK.

Clin Pharmacokinet. 2009;48(11):745-58. doi: 10.2165/11318060-000000000-00000.

PMID:
19817503
11.

Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil.

Zahr N, Arnaud L, Marquet P, Haroche J, Costedoat-Chalumeau N, Hulot JS, Funck-Brentano C, Piette JC, Amoura Z.

Arthritis Rheum. 2010 Jul;62(7):2047-54. doi: 10.1002/art.27495.

12.

Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9.

Jiao Z, Ding JJ, Shen J, Liang HQ, Zhong LJ, Wang Y, Zhong MK, Lu WY.

Br J Clin Pharmacol. 2008 Jun;65(6):893-907. doi: 10.1111/j.1365-2125.2008.03109.x. Epub 2008 Feb 15.

13.

Mechanism-based enterohepatic circulation model of mycophenolic acid and its glucuronide metabolite: assessment of impact of cyclosporine dose in Asian renal transplant patients.

Yau WP, Vathsala A, Lou HX, Zhou S, Chan E.

J Clin Pharmacol. 2009 Jun;49(6):684-99. doi: 10.1177/0091270009332813. Epub 2009 Apr 22.

PMID:
19386625
14.

Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus.

Djabarouti S, Duffau P, Lazaro E, Chapouly C, Greib C, Viallard JF, Pellegrin JL, Saux MC, Breilh D.

Expert Opin Pharmacother. 2010 Apr;11(5):689-99. doi: 10.1517/14656561003592144.

PMID:
20210680
16.

Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients.

Kuypers DR, Ekberg H, Grinyó J, Nashan B, Vincenti F, Snell P, Mamelok RD, Bouw RM.

Clin Pharmacokinet. 2009;48(5):329-41. doi: 10.2165/00003088-200948050-00005.

PMID:
19566116
17.

Mycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic study.

Roland M, Barbet C, Paintaud G, Magdelaine-Beuzelin C, Diot E, Halimi JM, Lebranchu Y, Nivet H, Büchler M.

Lupus. 2009 Apr;18(5):441-7. doi: 10.1177/0961203308098631.

PMID:
19318398
18.

The magnitude and time course of changes in mycophenolic acid 12-hour predose levels during antibiotic therapy in mycophenolate mofetil-based renal transplantation.

Borrows R, Chusney G, Loucaidou M, James A, Van Tromp J, Cairns T, Griffith M, Hakim N, McLean A, Palmer A, Papalois V, Taube D.

Ther Drug Monit. 2007 Feb;29(1):122-6.

PMID:
17304160
20.

Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.

de Winter BC, van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RA.

J Pharmacokinet Pharmacodyn. 2009 Dec;36(6):541-64. doi: 10.1007/s10928-009-9136-6. Epub 2009 Nov 11.

Supplemental Content

Support Center